Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020;58(Suppl S29):1–464.

PubMed  Google Scholar 

Johansson L, Akerlund A, Holmberg K, Melén I, Bende M. Prevalence of nasal polyps in adults: the Skövde population-based study. Ann Otol Rhinol Laryngol. 2003;112(7):625–9.

Article  PubMed  Google Scholar 

Sanchez-Collado I, Mora T, Munoz-Cano R, Ribo P, Mullol J, Valero A. Prevalence of chronic rhinosinusitis with nasal polyps in Catalonia (Spain): a retrospective, large-scale population-based study. Rhinology. 2022;60(5):384–96.

CAS  PubMed  Google Scholar 

Dietz de Loos D, Lourijsen ES, Wildeman MAM, Freling NJM, Wolvers MDJ, Reitsma S, et al. Prevalence of chronic rhinosinusitis in the general population based on sinus radiology and symptomatology. J Allergy Clin Immunol. 2019;143(3):1207–14.

Article  PubMed  Google Scholar 

Calus L, Van Bruaene N, Bosteels C, Dejonckheere S, Van Zele T, Holtappels G, et al. Twelve-year follow-up study after endoscopic sinus surgery in patients with chronic rhinosinusitis with nasal polyposis. Clin Transl Allergy. 2019;9:30.

Article  PubMed  PubMed Central  Google Scholar 

Hopkins C, Slack R, Lund V, Brown P, Copley L, Browne J. Long-term outcomes from the English national comparative audit of surgery for nasal polyposis and chronic rhinosinusitis. Laryngoscope. 2009;119(12):2459–65.

Article  PubMed  Google Scholar 

Tomassen P, Vandeplas G, Van Zele T, Cardell LO, Arebro J, Olze H, et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol. 2016;137(5):1449–56.e4.

Article  CAS  PubMed  Google Scholar 

Wang X, Zhang N, Bo M, Holtappels G, Zheng M, Lou H, et al. Diversity of TH cytokine profiles in patients with chronic rhinosinusitis: a multicenter study in Europe, Asia, and Oceania. J Allergy Clin Immunol. 2016;138(5):1344–53.

Article  CAS  PubMed  Google Scholar 

Liao B, Liu JX, Li ZY, Zhen Z, Cao PP, Yao Y, et al. Multidimensional endotypes of chronic rhinosinusitis and their association with treatment outcomes. Allergy. 2018;73(7):1459–69.

Article  CAS  PubMed  Google Scholar 

Wang X, Sima Y, Zhao Y, Zhang N, Zheng M, Du K, et al. Endotypes of chronic rhinosinusitis based on inflammatory and remodeling factors. J Allergy Clin Immunol. 2023;151(2):458–68.

Article  CAS  PubMed  Google Scholar 

Wang H, Li ZY, Jiang WX, Liao B, Zhai GT, Wang N, et al. The activation and function of IL-36gamma in neutrophilic inflammation in chronic rhinosinusitis. J Allergy Clin Immunol. 2018;141(5):1646–58.

Article  CAS  PubMed  Google Scholar 

Stevens WW, Peters AT, Tan BK, Klingler AI, Poposki JA, Hulse KE, et al. Associations between inflammatory endotypes and clinical presentations in chronic rhinosinusitis. J Allergy Clin Immunol Pract. 2019;7(8):2812–20.e3.

Article  PubMed  PubMed Central  Google Scholar 

Min JY, Kim JY, Sung CM, Kim ST, Cho HJ, Mun SJ, et al. Inflammatory endotypes of chronic rhinosinusitis in the Korean population: distinct expression of type 3 inflammation. Allergy Asthma Immunol Res. 2023;15(4):437–50.

Article  PubMed  PubMed Central  Google Scholar 

Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638–50.

Article  CAS  PubMed  Google Scholar 

Han JK, Bachert C, Fokkens W, Desrosiers M, Wagenmann M, Lee SE, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021;9(10):1141–53.

Article  CAS  PubMed  Google Scholar 

Xu X, Reitsma S, Wang Y, Fokkens WJ. Updates in biologic therapy for chronic rhinosinusitis with nasal polyps and NSAID-exacerbated respiratory disease. Allergy. 2022;77(12):3593–605.

Article  CAS  PubMed  Google Scholar 

Gevaert P, Omachi TA, Corren J, Mullol J, Han J, Lee SE, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol. 2020;146(3):595–605.

Article  CAS  PubMed  Google Scholar 

Delemarre T, Holtappels G, De Ruyck N, Zhang N, Nauwynck H, Bachert C, et al. A substantial neutrophilic inflammation as regular part of severe type 2 chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2021;147(1):179–88.e2.

Article  CAS  PubMed  Google Scholar 

Ruan JW, Zhao JF, Li XL, Liao B, Pan L, Zhu KZ, et al. Characterizing the neutrophilic inflammation in chronic rhinosinusitis with nasal polyps. Front Cell Dev Biol. 2021;9:793073.

Article  PubMed  PubMed Central  Google Scholar 

Kim DK, Lim HS, Eun KM, Seo Y, Kim JK, Kim YS, et al. Subepithelial neutrophil infiltration as a predictor of the surgical outcome of chronic rhinosinusitis with nasal polyps. Rhinology. 2021;59(2):173–80.

PubMed  Google Scholar 

Wen W, Liu W, Zhang L, Bai J, Fan Y, Xia W, et al. Increased neutrophilia in nasal polyps reduces the response to oral corticosteroid therapy. J Allergy Clin Immunol. 2012;129(6):1522–8.e5.

Article  CAS  PubMed  Google Scholar 

Kolkhir P, Akdis CA, Akdis M, Bachert C, Bieber T, Canonica GW, et al. Type 2 chronic inflammatory diseases: targets, therapies and unmet needs. Nat Rev Drug Discov. 2023;22(9):743–67.

Article  CAS  PubMed  Google Scholar 

Stevens WW, Kato A. Group 2 innate lymphoid cells in nasal polyposis. Ann Allergy Asthma Immunol. 2021;126(2):110–7.

Article  CAS  PubMed  Google Scholar 

Akdis CA. Does the epithelial barrier hypothesis explain the increase in allergy, autoimmunity and other chronic conditions? Nat Rev Immunol. 2021;21(11):739–51.

Article  CAS  PubMed  Google Scholar 

Mukai K, Tsai M, Saito H, Galli SJ. Mast cells as sources of cytokines, chemokines, and growth factors. Immunol Rev. 2018;282(1):121–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vanderhaegen T, Gengler I, Dendooven A, Chenivesse C, Lefèvre G, Mortuaire G. Eosinophils in the field of nasal polyposis: towards a better understanding of biologic therapies. Clin Rev Allergy Immunol. 2022;62(1):90–102.

Article  CAS  PubMed  Google Scholar 

Weller PF, Spencer LA. Functions of tissue-resident eosinophils. Nat Rev Immunol. 2017;17(12):746–60.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tsuda T, Maeda Y, Nishide M, Koyama S, Hayama Y, Nojima S, et al. Eosinophil-derived neurotoxin enhances airway remodeling in eosinophilic chronic rhinosinusitis and correlates with disease severity. Int Immunol. 2019;31(1):33–40.

Article  CAS  PubMed  Google Scholar 

Wu Q, Zhang Y, Kong W, Wang X, Yuan L, Zheng R, et al. Which is the best biologic for nasal polyps: dupilumab, omalizumab, or mepolizumab? A network meta-analysis. Int Arch Allergy Immunol. 2022;183(3):279–88.

Article  CAS  PubMed  Google Scholar 

Bachert C, Han JK, Desrosiers MY, Gevaert P, Heffler E, Hopkins C, et al. Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2022;149(4):1309–17.e12.

Article  CAS  PubMed  Google Scholar 

Gevaert P, Lang-Loidolt D, Lackner A, Stammberger H, Staudinger H, Van Zele T, et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol. 2006;118(5):1133–41.

Article  CAS  PubMed  Google Scholar 

Jonstam K, Swanson BN, Mannent LP, Cardell LO. Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis. Allergy. 2019;74(4):743–52.

Article  CAS  PubMed  Google Scholar 

Wright JD, Chu HM, Huang CH, Ma C, Chang TW, Lim C. Structural and physical basis for anti-IgE therapy. Sci Rep. 2015;5:11581.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Silverberg JI, Guttman-Yassky E, Thaçi D, Irvine AD, Stein Gold L, Blauvelt A, et al. Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med. 2023;388(12):1080–91.

Article  CAS  PubMed  Google Scholar 

Paller AS, Flohr C, Cork M, Bewley A, Blauvelt A, Hong HC, et al. Efficacy and safety of tralokinumab in adolescents with moderate to severe atopic dermatitis: the phase 3 ECZTRA 6 randomized clinical trial. JAMA Dermatol. 2023;159(6):596–605.

Article  PubMed  PubMed Central  Google Scholar 

Mullard A. FDA approves first-in-class TSLP-targeted antibody for severe asthma. Nat Rev Drug Discov. 2022;21(2):89.

PubMed